Nestlé has divested its peanut allergy treatment business, Palforzia, to biopharmaceutical company Stallergenes Greer.
Headquartered in Switzerland, Stallergenes Greer specialises in the diagnosis and treatment of respiratory allergies through immunotherapy.
The deal follows Nestlé’s announcement last year, stating its intention to undertake a strategic review of Palforzia. The food giant said it will “receive milestone payments and ongoing royalties” from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said: “We are confident that Stallergenes Greer will take Palforzia forward and ensure this unique treatment supports patients around the world. At the same time, the divestiture allows Nestlé Health Science to focus on its core strengths and key growth drivers.”
According to the company, a customary transition period will be implemented to ensure business continuity and to provide patients with uninterrupted access to the treatment.
Terms of the transaction were not disclosed.
By Rafaela Sousa
Paine Schwartz Partners has closed on a Paine Schwartz Food Chain Fund VI, L.P. at $1.7 billion. The fund is aimed at investing in the food and agribusiness value chain. The company has invested about 40% of Fund VI in AgroFresh Solutions, Costa Group, Elemental Enzymes, HGS BioScience and Monterey Mushrooms.
After 26 years in Geneva, Switzerland, the decision to move has been made after visitor and exhibitor feedback, as well as growth plans for the Vitafoods brand. Vitafoods Europe 2025 will be held on 20-22 May 2025 at Fira Barcelona, with more details to be announced next year.
The traditional symbol of family reunion and cultural pastry of Asia is undergoing a reinvention. With the majority of young consumers in Asia expressing an increasing interest in healthier options, a growing market for mooncakes tailored to dietary preferences and restrictions is opening up across the globe.